pembrolizumab + paclitaxel + carboplatin + bevacizumab

This is a **four-drug combination regimen** comprising pembrolizumab, paclitaxel, carboplatin, and bevacizumab, used primarily for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumors express PD-L1 (combined positive score [CPS] ≥1). - **Pembrolizumab** is a monoclonal antibody that inhibits programmed death 1 (PD-1), enhancing immune cell activity against cancer cells. - **Paclitaxel** is a microtubule inhibitor, disrupting mitosis. - **Carboplatin** is a platinum-based chemotherapy that causes DNA cross-linking and cell death. - **Bevacizumab** is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis in tumors. This regimen is administered intravenously and is typically indicated when platinum-based chemotherapy and anti-angiogenic therapy are used together with immunotherapy for eligible patients. It is supported by pivotal clinical trial data (e.g., KEYNOTE-826) and is approved in the United States and Europe for certain populations of cervical cancer patients[1][2][3].